Shilpa Medicare Opens Flow Chemistry Centre in Bengaluru

Shilpa Medicare, a full-service CDMO (Contract Development and Manufacturing Organization), has launched its new Flow Chemistry Centre of Excellence (CoE) at its Bengaluru site in Dobbespet, Avarahalli Industrial Area.

The announcement was made at CPHI Frankfurt 2025, where Shilpa Medicare is present at Ground Level, Hall 3, Booth C2. The Flow Chemistry CoE brings together R&D and manufacturing teams to speed up process development, scale-up, and commercial production for continuous flow operations.

 The centre is now fully operational and open for client collaborations, offering services in process development, technology transfer, and commercial manufacturing.

Also Read: India's Innovative Therapies Set Global Standard at Low Cost

Vishnukant Bhutada, Managing Director of Shilpa Medicare, said flow technology is in high demand among CDMOs because it allows safe handling of hazardous reactions and supports sustainable, efficient production. He added that it helps deliver faster and more reliable results, making it vital for developing oncology intermediates and other complex products.

With a team of over 100 specialists, the CoE integrates Sravathi’s proprietary flow technologies, including continuous reactor platforms. These systems support complex reactions such as fluorination, bromination, nitration, chlorination, oxidation, and Grignard reactions. Sravathi’s group has developed over 30 flow-based reactions and transferred more than five pilot-scale processes to clients for commercial manufacturing.

The facility features more than 50 patented, custom-designed reactors with capacities from 30 mL/min to 200 mL/min. These systems safely handle multi-phase and gas–liquid reactions under corrosion-resistant materials. Automated temperature and pressure monitoring allows remote control, ensuring accuracy and scalability.

Here is what industry leaders say about flow chemistry adoption

Sudhir Pillai, Managing Director of Corning India, underscored Corning's commitment to educating students and industry partners on the advantages of continuous flow chemistry using their technology and believes that joining the Flow Chemistry Technology Hub will further the pharmaceutical industry in India.

Avinash Goyal, Senior Partner at McKinsey & Company, has commented on broader trends in the Indian chemical industry, stating that consolidation and scaling companies will have more global opportunities. While not a direct quote on flow chemistry, this perspective aligns with the technological advancements that flow chemistry supports.